ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Tagrisso shows 'unprecedented' disease free survival in lung cancer pharmatimes
June 01, 2020According to AstraZeneca, its EGFR inhibitor Tagrisso (osimertinib) has shown 'unprecedented disease-free survival' in the adjuvant treatment of patients with EGFR-mutated lung cancer. -
Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer worldpharmanews
September 05, 2019AstraZeneca announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-line treatment for adults with locally-advanced... -
Higher eGFR at Dialysis Initiation Tied to Lower Survival in Children drugs
July 22, 2019Higher eGFR at Dialysis Initiation Tied to Lower Survival in Children. -
Taiho Pharmaceutical licences lung cancer drug to Cullinan Oncology pharmaceutical-technology
February 20, 2019Japan-based Taiho Pharmaceutical has signed an agreement to licence its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor candidate TAS6417 for lung cancer to Cullinan Oncology.... -
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
worldpharmanews
September 28, 2018Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth fact -
Tarloxitinib puts tumour-seeking tail on anti-EGFR drug to target lung cancer
europeanpharmaceuticalreview
October 26, 2017Researchers have proposed a unique way to reach the concentration of anti-EGFR drug needed to fight exon 20 insertions without harming healthy tissues… -
AstraZeneca lung cancer drug proves able to shrink EGFR mutation-positive tumours
pharmafile
October 18, 2017AstraZeneca and its partner and Chinese medicine (also known as Chi-Med) have announced positive data on savolitinib combined with AstraZeneca's Tagrisso or Iressa
Pharma Sources Insight July 2025
